Liposomal Bupivacaine for Preventing Atrial Fibrillation
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.
Who Is on the Research Team?
Juan G. Ripoll Sanz, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-surgical Treatment
Participants receive pre-surgical stellate ganglion blockade with liposomal bupivacaine or a saline placebo
Postoperative Monitoring
Participants are monitored for postoperative atrial fibrillation using continuous ECG monitoring
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Stellate Ganglion Blockade with Liposomal Bupivacaine
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
10 mL of liposomal bupivacaine 133 mg (133 mg/10 ml or 1.33%)
10 mL of saline placebo injected in the plane of the right stellate ganglion
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.